Previous Article | Next Article 
Journal of Virology, October 1999, p. 8808-8812, Vol. 73, No. 10
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Cell Surface Expression of Biologically Active
Influenza C Virus HEF Glycoprotein Expressed from cDNA
Andrew
Pekosz1 and
Robert A.
Lamb1,2,*
Howard Hughes Medical
Institute1 and Department of
Biochemistry, Molecular Biology and Cell
Biology,2 Northwestern University, Evanston,
Illinois 60208-3500
Received 25 May 1999/Accepted 8 July 1999
 |
ABSTRACT |
The hemagglutinin, esterase, and fusion (HEF) glycoprotein of
influenza C virus possesses receptor binding, receptor destroying, and
membrane fusion activities. The HEF cDNAs from influenza C/Ann Arbor/1/50 (HEF-AA) and influenza C/Taylor/1223/47 (HEF-Tay) viruses were cloned and expressed, and transport of HEF to the cell surface was
monitored by susceptibility to cleavage by exogenous trypsin, indirect
immunofluorescence microscopy, and flow cytometry. Previously it has
been found in studies with the C/Johannesburg/1/66 strain of influenza
C virus (HEF-JHB) that transport of HEF to the cell surface is severely
inhibited, and it is thought that the short cytoplasmic tail,
Arg-Thr-Lys, is involved in blocking HEF cell surface expression (F. Oeffner, H.-D. Klenk, and G. Herrler, J. Gen. Virol. 80:363-369,
1999). As the cytoplasmic tail amino acid sequences of HEF-AA and
HEF-Tay are identical to that of HEF-JHB, the data indicate that cell
surface expression of HEF-AA and HEF-Tay is not inhibited by this amino
acid sequence. Furthermore, the abundant cell surface transport of
HEF-AA and HEF-Tay indicates that their cell surface expression does
not require coexpression of another viral protein. The HEF-AA and
HEF-Tay HEF glycoproteins bound human erythrocytes, promoted membrane
fusion in a low-pH and trypsin-dependent manner, and displayed esterase
activity, indicating that the HEF glycoprotein alone mediates all three known functions at the cell surface.
 |
TEXT |
Influenza A, B, and C viruses are
negative-strand, segmented RNA viruses of the
Orthomyxoviridae family, differing primarily in the number
of integral membrane proteins encoded by the viral genome (reviewed in
reference 10). Whereas influenza A and B viruses
encode three integral membrane proteins, hemagglutinin (HA),
neuraminidase (NA), and M2 (influenza A virus) or NB
(influenza B virus), influenza C viruses encode only two integral
membrane proteins, HEF and CM2 (9, 17). The lack of a
separate protein with receptor-destroying activity is reflected in the
influenza C virus genome by the concomitant loss of one RNA segment, as influenza C virus has seven RNA segments (18, 21).
The HEF glycoprotein is a homotrimer which mediates virion binding to
the viral receptor, 9-O-N-acetyl neuraminic acid
(7), possesses an acetylesterase or receptor-destroying
activity (8), and mediates membrane fusion between the
influenza C virus and cellular membranes after triggering by low-pH
treatment (3, 15). Fusion activity requires that the 90-kDa
precursor protein HEF0 be cleaved to the disulfide-linked
subunits HEF1 and HEF2 by unidentified cellular
protease(s). The recently solved atomic structure of HEF at 3.2 Å resolution shows a marked degree of structural similarity to that of
influenza A virus HA, despite very little amino acid homology between
the two proteins (22).
Analysis at the cell surface of the three biological activities of HEF
has been hindered by an apparent lack of surface transport of the
glycoprotein in mammalian cells when the cDNA was derived from
influenza C virus strain C/Johannesburg/1/66 (HEF-JHB) (14, 20,
25), although erythrocyte binding has been observed when the
C/California/78 HEF cDNA was expressed in cells (26). The lack of surface transport of HEF-JHB has been attributed to a negative
regulatory domain (Arg-Thr-Lys) which compromises the predicted
cytoplasmic tail of HEF (14). We have studied the expression
from cDNA of the HEF glycoproteins from influenza C/Ann Arbor/1/50
virus (HEF-AA) and influenza C/Taylor/1233/47 virus (HEF-Tay) and have
determined that the HEF glycoprotein of both strains is transported to
the cell surface and exhibits the three known biological activities of
HEF when expressed in a variety of cell types and in a variety of
expression systems. As HEF-JHB, HEF-AA, and HEF-Tay all possess the
same cytoplasmic tail amino acid sequence (2), we interpret
our data to indicate that the Arg-Thr-Lys motif is not inhibitory to
cell surface transport of HEF-AA and HEF-Tay and that the lack of cell
surface expression of the HEF-JHB protein represents either a virus
strain phenomenon or a peculiarity of the HEF-JHB cDNA nucleotide
sequence (19, 24).
The cDNAs for HEF were obtained by rt-PCR of vRNA from MDCK cell-grown
influenza C/AA/1/50 or influenza C/Taylor/1233/47 virus (data not
shown; primers were designed based on known influenza C virus RNA
segment 4 sequences) (2) and initially cloned into the
plasmid pGEM3, under control of the bacteriophage T7 RNA polymerase promoter (16). The pGEM3 HEF-AA plasmid was transfected into HeLa-T4 cells which were infected with a recombinant vaccinia virus
(vac-T7) expressing the bacteriophage T7 RNA polymerase (4).
The cells were metabolically labeled and incubated in chase medium as
previously described (16). At the indicated times, the cells
were lysed, and HEF protein was immunoprecipitated with a cocktail of
HEF-specific monoclonal antibodies (MAbs) (23). The HEF-AA
glycoprotein migrated as a single band of approximately 90 kDa under
reducing conditions (Fig. 1A) at all the
indicated times. Under nonreducing conditions, the
HEF-AA glycoprotein also migrated as a single 90-kDa band, although
some heterogeneity was detected after incubation in chase medium for 0, 10, and 20 min, most likely resulting from a lack of proper disulfide
bond formation. Conversion of HEF-AA from an 80- to a 100-kDa form under nonreducing conditions, an event associated with but not sufficient to confer cell surface transport of HEF-JHB (14, 25), was not observed.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 1.
(A) HeLa-T4 cells in 35-mm-diameter tissue culture
dishes were infected with vac-T7 at a multiplicity of infection of 5 to
10 PFU per cell for 1 h at 37°C and were then transfected with a
plasmid containing the cDNA for HEF-AA under the control of the T7 RNA
polymerase promoter (pGEM HEF-AA) as previously described
(16). At 5 h posttransfection, the cells were incubated
in Dulbecco's modified Eagle medium deficient in cysteine and
methionine, metabolically labelled with [35S]ProMix (100 µCi/ml) for 15 min, and incubated in chase medium for the
indicated times (16). The cells were lysed, polypeptides
were immunoprecipitated with a cocktail of anti-HEF MAbs, resuspended
in sample buffer with or without the reducing agent dithiothreitol
(DTT), and boiled for 5 min before analysis of polypeptides by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with 10%
acrylamide gels. (B) Vac-T7-infected, pGEM HEF-AA-transfected HeLa-T4
cells were metabolically labeled, and proteins were immunoprecipitated
as described above, the immune complexes were divided into two aliquots
and treated with endoglycosidase H (+) or untreated ( ) before the
analysis of polypeptides by SDS-PAGE on 10% acrylamide gels. (C)
Vac-T7 infected, pGEM HEF-AA-transfected HeLa-T4 cell lysates were
metabolically labeled as above. Ten minutes prior to the indicated
times, TPCK-trypsin (15 µg/ml) was added to the chase media to cleave
cell surface HEF0 into HEF1 and
HEF2 subunits. At the indicated times, the cells were
placed on ice and washed with phosphate-buffered saline containing a
cocktail of protease inhibitors, the cells were lysed, proteins were
immunoprecipitated, and polypeptides were separated by SDS-PAGE on 15%
acrylamide gels as described above. No trypsin was added to the 0-min
chase sample.
|
|
Intracellular transport of HEF-AA to the medial-Golgi
apparatus was assessed by determining the rate of resistance to
digestion by endoglycosidase H (endo H) of HEF carbohydrate chains in a pulse-chase protocol. HEF-AA began to acquire endo H-resistant carbohydrate modifications after 30 min (Fig. 1B) and reached a maximum
(approximately 70%) by 120 min indicating that the majority of the
metabolically labeled glycoprotein had been transported to the
medial-Golgi apparatus. Transport of HEF-AA glycoprotein to
the cell surface was investigated by monitoring the cleavage of
HEF0 into HEF1 and HEF2 subunits
(6) upon the addition of tosyl phenylalanyl chloromethyl
ketone (TPCK)-trypsin to the cell culture media (Fig. 1C).
HEF1 and HEF2 were detected 60 min after the
pulse-chase, indicating the arrival of HEF0 at the cell
surface. As 65% of the HEF-AA glycoprotein was cleaved into
HEF1 and HEF2 after 240 min, it is reasonable
to conclude that the majority of the HEF-AA glycoprotein is transported
to the cell surface when expressed from cDNA by using the vac-T7
expression system.
Cell surface expression of HEF-AA and HEF-Tay was also investigated by
using two different expression systems, recombinant simian virus 40 (rSV40) (5, 11, 12) and the eukaryotic expression vector
pCAGGS (13). The cDNAs for HEF-AA and HEF-Tay were subcloned
into the pCAGGS vector and expressed transiently as previously
described (17) or subcloned into the plasmid pSV133 and used
to generate rSV40s (12). CV-1 cells were infected with rSV40s expressing HEF-AA (Fig. 2A) or
HEF-Tay (Fig. 2B) or mock infected (Fig. 2C), whereas HeLa-T4 cells
were transfected with pCAGGS HEF-AA (Fig. 2D) or pCAGGS HEF-Tay (Fig.
2E) or mock transfected (Fig. 2F). At 36 h postinfection or
18 h posttransfection, the cells were fixed with 1% formaldehyde,
incubated with a cocktail of anti-HEF MAbs, followed by staining with
fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse
immunoglobulin G (IgG) and cell surface fluorescence assessed by using
a confocal microscope. HEF-AA and HEF-Tay were transported to the cell
surface when expressed by using either rSV40 or pCAGGS vectors as
indicated by the strong cell surface fluorescence signal compared to
mock-infected or transfected cells. Cell surface expression of HEF from
the eukaryotic expression vector pCAGGS was quantitated by flow
cytometry. At 18 h posttransfection, mock-transfected,
pCAGGS HEF-AA-transfected, or pCAGGS HEF-Tay-transfected
Vero cells were incubated with a cocktail of anti-HEF MAbs,
followed by an FITC-conjugated goat anti-mouse IgG and analyzed by flow
cytometry. Vero cells transfected with pCAGGS HEF-AA (Fig. 2G) or
pCAGGS HEF-Tay (Fig. 2H) showed a large increase in cell surface
fluorescence compared to mock-transfected cells. Quantitation of the
histograms in Fig. 2G and H yielded 54.6% positive cells and a mean
channel fluorescence of 179.8 for pCAGGS HEF-AA-transfected cells and
56.2% positive cells and a mean channel fluorescence of 169.8 for
pCAGGS HEF-Tay-transfected cells (mock-transfected cells were
arbitrarily set at a mean channel fluorescence of 3.5). The data shown
in Fig. 1 and 2 indicate that the HEF-AA or HEF-Tay glycoproteins are
transported to the cell surface when expressed in a variety of
expression systems and cell types.

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 2.
CV-1 cells grown on glass coverslips in 35-mm-diameter
culture dishes were infected with rSV40 HEF-AA (A), rSV40 HEF-Tay (B),
or mock infected (C) and incubated at 37°C for 36 h. HeLa-T4
cells were transfected with pCAGGS HEF-AA (D) pCAGGS HEF-Tay (E), or
mock transfected (F) and incubated at 37°C for 18 h. Cell
monolayers were fixed with 1% formaldehyde in phosphate-buffered
saline, and surface HEF glycoprotein was detected by indirect
immunofluorescence (16) by using a 1:500 dilution of an
anti-HEF MAb cocktail followed by FITC-conjugated goat anti-mouse IgG
and visualized with a Zeiss LSM 410 confocal microscope. Bar, 25 µM.
Quantitation of HEF cell surface expression in Vero cells transfected
with pCAGGS HEF-AA (G) or pCAGGS HEF-Tay (H). At 18 h
posttransfection, the cells were incubated with a 1:500 dilution of a
cocktail of anti-HEF MAbs, followed by FITC-conjugated goat anti-mouse
IgG, and analyzed by flow cytometry. The relative fluorescence
intensity of 10,000 cells is depicted in the histograms. For
comparative purposes, each histogram displays the relative fluorescence
of mock-transfected Vero cells (thin line, same population in each
histogram) as well as cells transfected with the indicated plasmids
(thick line).
|
|
To determine whether expression of HEF from cDNA resulted in cell
surface accumulation of a functional glycoprotein, HEF-AA and HEF-Tay
glycoproteins were tested for receptor-binding and fusion activities by
using a modified lipid mixing assay involving fusion of
glycoprotein-expressing cells to octadecyl rhodamine B (R-18)-labeled
human erythrocytes (1). Vero cells transfected with plasmids
encoding pCAGGS HEF-AA (Fig. 3A and B) or
pCAGGS HEF-Tay (Fig. 3C and D) were assayed at 18 h
posttransfection for binding to and fusion with R-18-labeled human
erythrocytes as previously described (1). Both HEF-AA- and
HEF-Tay-expressing cells were able to bind R-18-labeled human
erythrocytes (Fig. 3A and C) and displayed trypsin-dependent cleavage
and low pH-induced fusion, as assayed by the transfer of R-18 dye from
the bound erythrocytes to the Vero cell plasma membranes (Fig. 3B and
D). HEF esterase activity was analyzed by using a commercially
available
-naphthyl esterase/Fast Blue BB detection kit, which
results in the formation of a dark precipitate on the surface of cells possessing esterase activity. As shown in Fig. 3, cells transfected with pCAGGS HEF-AA (Fig. 3F) and pCAGGS HEF-Tay (Fig. 3G) showed a
precipitate indicating expressed esterase activity, whereas cells
transfected with pCAGGS vector alone (Fig. 3E) showed no detectable
precipitate. Thus, the data indicate that HEF glycoprotein expressed at
the cell surface from the HEF cDNA is biologically functional.

View larger version (75K):
[in this window]
[in a new window]
|
FIG. 3.
Vero cells were grown on glass coverslips in
35-mm-diameter culture dishes, transfected with pCAGGS HEF-AA (A and B)
or pCAGGS HEF-Tay (C and D) as described previously (17),
and treated as indicated with TPCK-trypsin (15 µg/ml) for 15 min at
18 h posttransfection. Human erythrocytes labeled with octadecyl
rhodamine B (R18) were then added to the cells and incubated at 4°C
for 30 min (1). The cells were washed extensively with
phosphate-buffered saline, pH 7.4, incubated in phosphate-buffered
saline, pH 5.4 for 10 min at 37°C, and analyzed immediately for lipid
mixing by using a confocal microscope. Vero cells were grown on glass
coverslips in 35-mm culture dishes, transfected with pCAGGS vector
alone (E), pCAGGS HEF-AA (F), or pCAGGS HEF-Tay (E) as previously
described (17), and analyzed at 18 h posttransfection
with an -naphthyl esterase detection kit (Sigma Diagnostics, St.
Louis, Mo.) as per manufacturer's instructions. The cells were
photographed by using a Nikon Diaphot inverted, phase-contrast
microscope (Nikon Corp., Tokyo, Japan).
|
|
Our data contrast with previously published reports on the expression
of HEF-JHB from cDNA (14, 20, 25). When expressed from cDNA,
the HEF-JHB glycoprotein accumulates in an 80-kDa, presumably
misfolded, form and is retained in the endoplasmic reticulum
(25). Amino acid substitutions in or deletion of the HEF-JHB
cytoplasmic tail restored the 100-kDa form of the protein but failed to
restore cell surface transport, indicating conversion of the 80-kDa
form of HEF to the 100-kDa form alone was insufficient to promote cell
surface transport (25). Subsequently, Oeffner and colleagues
(14) showed that replacing the HEF cytoplasmic tail with
that of the influenza A virus HA or the cellular protein gp40 restored
both conversion to the 100-kDa form of HEF and cell surface transport,
implicating the HEF cytoplasmic tail as being inhibitory to cell
surface expression (14). It must be noted that the
Arg-Thr-Lys motif was not shown to be sufficient in and of itself to
prevent cell surface transport of other glycoproteins. Our data
indicate that the inhibitory effect of the HEF cytoplasmic tail on HEF
cell surface transport is an influenza C virus strain-specific phenomenon, since HEF-AA, HEF-Tay, and HEF-JHB contain the exact same
cytoplasmic tail amino acid sequence (2). It remains to be
determined whether coexpression of some other viral protein is required
for HEF-JHB cell surface transport or whether any of the amino acid
differences between the original HEF-JHB sequence (19) and
that used by Szepanski and colleagues (24) perturb the
folding and/or intracellular transport of the HEF-JHB protein.
 |
ACKNOWLEDGMENTS |
We thank K. Nakamura, Yamagata University School of Medicine,
Japan, for the generous gift of anti-HEF monoclonal antibodies and the
members of the Lamb laboratory for helpful discussions.
This research was supported by research grant R37 AI-20201 from the
National Institute of Allergy and Infectious Diseases. A.P. is an
associate and R.A.L. is an investigator at the Howard Hughes Medical Institute.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Biochemistry, Molecular Biology and Cell Biology, Northwestern
University, 2153 North Campus Dr., Evanston, IL 60208-3500. Phone:
(847) 491-5433. Fax: (847) 491-2467. E-mail: ralamb{at}nwu.edu.
 |
REFERENCES |
| 1.
|
Bagai, S., and R. A. Lamb.
1995.
Quantitative measurement of paramyxovirus fusion: differences in requirements of glycoproteins between simian virus 5 and human parainfluenza virus 3 or Newcastle disease virus.
J. Virol.
69:6712-6719[Abstract].
|
| 2.
|
Buonagurio, D. A.,
S. Nakada,
U. Desselberger,
M. Krystal, and P. Palese.
1985.
Noncumulative sequence changes in the hemagglutinin genes of influenza C virus isolates.
Virology
146:221-232[Medline].
|
| 3.
|
Formanowski, F.,
S. A. Wharton,
L. J. Calder,
C. Hofbauer, and H. Meier-Ewert.
1990.
Fusion characteristics of influenza C viruses.
J. Gen. Virol.
71:1181-1188[Abstract/Free Full Text].
|
| 4.
|
Fuerst, T. R.,
E. G. Niles,
F. W. Studier, and B. Moss.
1986.
Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.
Proc. Natl. Acad. Sci. USA
83:8122-8126[Abstract/Free Full Text].
|
| 5.
|
Gething, M. J., and J. Sambrook.
1981.
Cell-surface expression of influenza haemagglutinin from a cloned DNA copy of the RNA gene.
Nature
293:620-625[Medline].
|
| 6.
|
Herrler, G.,
R. W. Compans, and H. Meier-Ewert.
1979.
A precursor glycoprotein in influenza C virus.
Virology
99:49-56[Medline].
|
| 7.
|
Herrler, G., and H.-D. Klenk.
1987.
The surface receptor is a major determinant of the cell tropism of influenza C virus.
Virology
159:102-108[Medline].
|
| 8.
|
Herrler, G.,
R. Rott,
H.-D. Klenk,
H.-P. Muller,
A. K. Shukla, and R. Schauer.
1985.
The receptor-destroying enzyme of influenza C virus is neuraminate-O-acetyl esterase.
EMBO J.
4:2711-2720[Medline].
|
| 9.
|
Hongo, S.,
K. Sugawara,
H. Nishimura,
Y. Muraki,
F. Kitame, and K. Nakamura.
1994.
Identification of a second protein encoded by influenza C virus RNA segment 6.
J. Gen. Virol.
75:3503-3510[Abstract/Free Full Text].
|
| 10.
|
Lamb, R. A., and R. M. Krug.
1996.
Orthomyxoviridae: the viruses and their replication, p. 1353-1394.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology (3rd ed.). Lippincott-Raven Press, New York, N.Y.
|
| 11.
|
Lamb, R. A., and C.-J. Lai.
1982.
Spliced and unspliced messenger RNAs synthesized from cloned influenza virus M DNA in an SV40 vector: expression of the influenza virus membrane protein (M1).
Virology
123:237-256[Medline].
|
| 12.
|
Naim, H. Y., and M. G. Roth.
1994.
SV40 virus expression vectors.
Methods Cell Biol.
43:113-136.
|
| 13.
|
Niwa, H.,
K. Yamamura, and J. Miyazaki.
1991.
Efficient selection for high-expression transfectants by a novel eukaryotic vector.
Gene
108:193-200[Medline].
|
| 14.
|
Oeffner, F.,
H. D. Klenk, and G. Herrler.
1999.
The cytoplasmic tail of the influenza C virus glycoprotein HEF negatively affects transport to the cell surface.
J. Gen. Virol.
80:363-369[Abstract].
|
| 15.
|
Ohuchi, M.,
R. Ohuchi, and K. Mifune.
1982.
Demonstration of hemolytic and fusion activities of influenza C virus.
J. Virol.
42:1076-1079[Abstract/Free Full Text].
|
| 16.
|
Pekosz, A., and R. A. Lamb.
1997.
The CM2 protein of influenza C virus is an oligomeric integral membrane glycoprotein structurally analogous to influenza A virus M2 and influenza B virus NB proteins.
Virology
237:439-451[Medline].
|
| 17.
|
Pekosz, A., and R. A. Lamb.
1998.
Influenza C virus CM2 integral membrane glycoprotein is produced from a polypeptide precursor by cleavage of an internal signal sequence.
Proc. Natl. Acad. Sci. USA
95:13233-13238[Abstract/Free Full Text].
|
| 18.
|
Petri, T.,
H. Meier-Ewert,
W. M. Crumpton, and N. J. Dimmock.
1979.
RNA'S of influenza C virus strains.
Arch. Virol.
61:239-243[Medline].
|
| 19.
|
Pfeifer, J. B., and R. W. Compans.
1984.
Structure of the influenza C glycoprotein gene as determined from cloned DNA.
Virus Res.
1:281-296[Medline].
|
| 20.
|
Pleschka, S.,
H. D. Klenk, and G. Herrler.
1995.
The catalytic triad of the influenza C virus glycoprotein HEF esterase: characterization by site-directed mutagenesis and functional analysis.
J. Gen. Virol.
76:2529-2537[Abstract/Free Full Text].
|
| 21.
|
Racaniello, V. R., and P. Palese.
1979.
Isolation of influenza C virus recombinants.
J. Virol.
32:1006-1014[Abstract/Free Full Text].
|
| 22.
|
Rosenthal, P. B.,
X. Zhang,
F. Formanowski,
W. Fitz,
C.-H. Wong,
H. Meier-Ewert,
J. J. Skehel, and D. C. Wiley.
1998.
Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus.
Nature
396:92-96[Medline].
|
| 23.
|
Sugawara, K.,
H. Nishimura,
F. Kitame, and K. Nakamura.
1986.
Antigenic variation among human strains of influenza C virus detected with monoclonal antibodies to gp88 glycoprotein.
Virus Res.
6:27-32[Medline].
|
| 24.
|
Szepanski, S.,
H. J. Gross,
R. Brossmer,
H. D. Klenk, and G. Herrler.
1992.
A single point mutation of the influenza C virus glycoprotein (HEF) changes the viral receptor-binding activity.
Virology
188:85-92[Medline].
|
| 25.
|
Szepanski, S.,
M. Veit,
S. Pleschka,
H. D. Klenk,
M. F. Schmidt, and G. Herrler.
1994.
Post-translational folding of the influenza C virus glycoprotein HEF: defective processing in cells expressing the cloned gene.
J. Gen. Virol.
75:1023-1030[Abstract/Free Full Text].
|
| 26.
|
Vlasak, R.,
M. Krystal,
M. Nacht, and P. Palese.
1987.
The influenza C virus glycoprotein (HE) exhibits receptor-binding (hemagglutinin) and receptor-destroying (esterase) activities.
Virology
160:419-425[Medline].
|
Journal of Virology, October 1999, p. 8808-8812, Vol. 73, No. 10
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Hanika, A., Larisch, B., Steinmann, E., Schwegmann-Wessels, C., Herrler, G., Zimmer, G.
(2005). Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes. J. Gen. Virol.
86: 1455-1465
[Abstract]
[Full Text]
-
Simmons, G., Reeves, J. D., Rennekamp, A. J., Amberg, S. M., Piefer, A. J., Bates, P.
(2004). Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci. USA
101: 4240-4245
[Abstract]
[Full Text]
-
Zhang, J., Pekosz, A., Lamb, R. A.
(2000). Influenza Virus Assembly and Lipid Raft Microdomains: a Role for the Cytoplasmic Tails of the Spike Glycoproteins. J. Virol.
74: 4634-4644
[Abstract]
[Full Text]